Related Experiment Videos
[Inflammatory mediators in patients with biventricular assist device systems]
D Hasper1, M Hummel, W D Döcke
1Institut für Medizinische Immunologie, Universitätsklinikum Charité, Berlin.
Zeitschrift Fur Kardiologie
|November 1, 1996
Summary
Systemic inflammation, indicated by elevated cytokines and adhesion molecules, occurs in cardiogenic shock. Mechanical circulatory support with a Biventricular Assist Device System (BVAD) can reduce these markers, suggesting improved outcomes.
Area of Science:
- Biomedical Engineering
- Immunology
- Cardiology
Context:
- Cardiogenic shock is a critical condition characterized by systemic inflammation.
- Mechanical circulatory support (MCS) is used to manage severe heart failure.
- Assessing inflammatory markers during MCS is crucial for patient management.
Purpose:
- To investigate plasma levels of inflammatory mediators and adhesion molecules in patients undergoing MCS with a Biventricular Assist Device System (BVAD).
- To compare these levels with patients with chronic heart failure and coronary artery disease.
- To evaluate the prognostic value of inflammatory markers during BVAD support.
Summary:
- Patients with cardiogenic shock exhibited elevated levels of Interleukin-6 (IL-6), Interleukin-8 (IL-8), and soluble adhesion molecules before MCS.
- Successful MCS with BVAD led to decreased inflammatory mediator levels, whereas persistently high levels indicated a fatal outcome.
- Systemic inflammation in cardiogenic shock may stem from hypoxia, and its persistence during MCS suggests device failure.
Impact:
- Monitoring inflammatory mediators may serve as a prognostic marker for patients with cardiogenic shock on MCS.
- Findings highlight the link between hypoxia, systemic inflammation, and outcomes in severe heart failure.
- This research contributes to understanding the inflammatory response to critical illness and mechanical support.